Clinical trial NCT06344390: Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke
Official title: Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke and Its Mechanism of Brain Electricity and Brain Metabolism
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Cognitive Impairment
Lead sponsor: The First Hospital of Hebei Medical University
Sponsor class: OTHER
First posted: 2024-04-03
Enrollment: 200
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke.

Detailed description: Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function.

Eligibility criteria: Inclusion Criteria:

* Han Chinese, age 40-80 years old, male and female, right-handed;
* The diagnosis is consistent with the Expert Consensus on the Management of Cognitive Impairment after Stroke 2021;
* NIHSS score 1-15 points;
* Daily Living Ability Scale (ADL) ≥75 score;
* The Informed consent signed by the patient or his legal representative

Exclusion Criteria:

* Can not cooperate with the examination (including neuropsychological tests and scale assessment);
* There were memory disorders, dementia with lewy bodies and frontotemporal dementia before the onset of stroke events;
* There were definite infectious diseases 2 weeks before admission; Have a serious mental illness, previous history of cancer, alcohol or drug abuse;
* Use of drugs that may affect cognitive function, including sedatives, anti-anxiety drugs, hypnotics, nootropic drugs, and cholinoid drugs;
* Can not accept brain MRI examination

Primary outcomes:
measure: Pentoxifylline can improve cognitive impairment after ischemic stroke
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Shijiazhuang
country: China
facility: BHan
Study officials:
affiliation: The First Hospital of Hebei Medical University
name: Jiaying Rong, master
role: PRINCIPAL_INVESTIGATOR
References: